Abivax SA American Depositary Shares (ABVX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.67B
Last updated: Nov 17, 2026 at 11:04 AM ET
Abivax SA American Depositary Shares (ABVX) Financials: Revenue, Profit and Cash Flow
Abivax SA American Depositary Shares reported revenue of EUR 0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was EUR -336.10M, operating cash flow was EUR -155.69M and free cash flow was EUR -155.83M. The quarter ended Jun 30, 2026 had revenue of EUR 0 and net income of EUR -117.43M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of EUR 246.06M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 0 | -100.0% | N/A | N/A | N/A |
| Dec 2024 | 10.79M | +133.5% | 100.0% | -1602.9% | -1633.1% |
| Dec 2023 | 4.62M | +0.8% | 99.0% | -2756.5% | -3197.1% |
| Dec 2022 | 4.58M | +12286.5% | -1107.7% | -1414.7% | -1325.3% |
| Dec 2021 | 37.00K | -41.3% | -123018.9% | -111891.9% | -114735.1% |
| Dec 2020 | 63.00K | +3050.0% | -53623.8% | -60330.2% | -59604.8% |
| Dec 2019 | 2.00K | -88.9% | -1409300.0% | -1664800.0% | -1531700.0% |
| Dec 2018 | 18.00K | +80.0% | -85327.8% | -106155.6% | -87905.6% |
| Dec 2017 | 10.00K | -92.1% | -144970.0% | -141500.0% | -112230.0% |
| Dec 2016 | 127.00K | N/A | -11431.5% | -14359.1% | -11266.1% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 10.79M | 4.62M | 4.58M | 37.00K | 63.00K | 2.00K | 18.00K | 10.00K | 127.00K |
| Cost of revenue | 1.03M | N/A | 707.00K | 50.76M | 45.52M | 33.78M | 28.19M | 15.38M | 14.51M | 14.64M |
| Gross profit | -1.03M | 10.79M | 4.57M | -50.76M | -45.52M | -33.78M | -28.19M | -15.36M | -14.50M | -14.52M |
| Research and development | 177.76M | 146.53M | 103.18M | 48.30M | 47.78M | 34.53M | 29.01M | 15.89M | 10.85M | 15.46M |
| Operating income | -246.06M | -172.98M | -127.38M | -64.84M | -41.40M | -38.01M | -33.30M | -19.11M | -14.15M | -18.24M |
| Net income | -336.10M | -176.24M | -147.74M | -60.74M | -42.45M | -37.55M | -30.63M | -15.82M | -11.22M | -14.31M |
| EBITDA | N/A | -162.71M | N/A | -53.31M | -38.59M | -38.00M | -33.22M | N/A | -13.98M | -17.86M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | -2.02M | 0 | 2.02M | 0 | 7.40M | 0 | 3.39M | 0 | 2.33M | 2.25M |
| Gross profit | N/A | N/A | -3.05M | N/A | 2.02M | N/A | 7.40M | N/A | 3.39M | N/A | 2.33M | 2.25M |
| Operating income | -84.11M | -56.23M | -199.56M | -80.71M | -46.50M | -47.20M | -47.20M | -50.19M | -35.33M | -44.67M | -92.46M | -39.53M |
| Net income | -117.43M | -48.47M | -287.69M | -153.36M | -48.41M | -52.37M | -52.37M | -55.23M | -38.77M | -42.87M | -95.79M | -51.95M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of EUR 29.40M by 487.07M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 584.09M | 205.23M | 327.06M | 75.54M | 109.23M | 71.30M | 51.73M | 54.05M | 53.81M | 60.60M |
| Current assets | 551.01M | 170.67M | 285.97M | 36.18M | 75.21M | 37.67M | 18.24M | 20.98M | 20.88M | 27.84M |
| Cash and equivalents | 516.47M | 144.22M | 251.94M | 26.95M | 60.70M | 29.30M | 9.77M | 8.00M | 1.88M | 7.94M |
| Total liabilities | 129.08M | 164.64M | 131.05M | 68.36M | 83.30M | 53.40M | 33.14M | 19.39M | 5.63M | 3.88M |
| Short-term debt | 29.40M | 43.77M | 31.26M | 30.03M | 10.23M | 12.00K | 20.74M | 10.90M | 170.00K | 255.00K |
| Long-term debt | N/A | 52.16M | 44.70M | 36.58M | 53.45M | 28.45M | 20.74M | N/A | N/A | N/A |
| Shareholder equity | 455.01M | 40.58M | 196.01M | 7.19M | 25.93M | 17.90M | 18.59M | 34.66M | 48.18M | 56.72M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Jun 2024 | Dec 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 462.21M | 547.14M | 652.05M | 652.05M | 119.64M | 166.94M | 205.23M | 284.49M | 327.06M | 171.08M | N/A | 75.54M |
| Total liabilities | 95.94M | 117.55M | 140.81M | 140.81M | 167.92M | 173.53M | 164.64M | 158.02M | 131.05M | 90.59M | N/A | 68.36M |
| Cash and equivalents | 387.99M | 477.42M | 516.47M | 589.70M | 60.95M | 103.58M | 144.22M | 222.32M | 251.94M | 114.38M | N/A | 26.95M |
| Shareholder equity | 366.27M | 429.59M | 455.01M | 511.24M | -48.28M | -6.59M | 40.58M | 126.47M | 196.01M | 80.49M | N/A | 7.19M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -155.69M | -154.07M | -100.01M | -53.94M | -45.05M | -29.82M | -27.47M | -14.60M | -8.45M | -15.61M |
| Capital expenditures | 136.40K | 643.00K | 265.00K | 323.00K | 47.00K | 898.00K | 941.00K | 763.00K | 979.00K | 721.00K |
| Free cash flow | -155.83M | -154.72M | -100.27M | -54.26M | -45.09M | -30.72M | -28.41M | -15.37M | -9.43M | -16.33M |
| Investing cash flow | -13.18M | 15.76M | -10.49M | -12.03M | -6.23M | -575.00K | -370.00K | -254.00K | -105.00K | -94.00K |
| Financing cash flow | 531.94M | 28.21M | 340.57M | 32.21M | 82.68M | 49.93M | 24.61M | 10.83M | 2.60M | -438.00K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -51.99M | -50.52M | -71.28M | -71.28M | -33.34M | -33.28M | -33.28M | -35.38M | -50.42M | -34.75M | -71.16M | -27.60M |
| Capital expenditures | 112.00K | 54.00K | 8.00K | 0 | 19.00K | 44.00K | 44.00K | 311.00K | 227.00K | 12.00K | 117.00K | 149.00K |
| Free cash flow | -52.10M | -50.57M | -71.29M | -71.28M | -33.36M | -33.32M | -33.32M | -35.69M | -50.65M | -34.77M | -71.28M | -27.75M |
Frequently Asked Questions About ABVX
What is Abivax SA American Depositary Shares' annual revenue?
Abivax SA American Depositary Shares reported revenue of EUR 0 for the fiscal year ended Dec 31, 2025.
How fast is Abivax SA American Depositary Shares' revenue growing?
Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Abivax SA American Depositary Shares profitable?
No. Abivax SA American Depositary Shares reported net income of EUR -336.10M for the fiscal year ended Dec 31, 2025.
How much free cash flow does ABVX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of EUR -155.69M minus capital expenditures of EUR 136.40K produced free cash flow of EUR -155.83M.
How much debt does Abivax SA American Depositary Shares have?
The balance sheet dated Dec 31, 2025 reported short-term debt of EUR 29.40M and cash and equivalents of EUR 516.47M.
ABVX pages: Overview, Financials, Competitors